Table 2

Details of initial corticosteroid therapy among hospitalised patients with COVID-19

Medical therapyOverall
(N=4313)
Survivors
(n=3043)
Non-survivors
(n=1270)
P value
Corticosteroids—n (%)574 (13.3)421 (13.8)153 (12.1)0.13
Medication
 Methylprednisolone282 (49.1)199 (73.3)83 (54.2)0.99
 Prednisone139 (24.2)109 (25.9)30 (19.6)0.04
 Dexamethasone82 (14.3)62 (14.7)20 (13.1)0.33
 Hydrocortisone71 (12.4)51 (12.1)20 (13.1)0.89
Duration of use (days)*
 Methylprednisolone6.63 (3.45–11.48)4.99 (2.89–8.33)5.80 (3.68–8.26)0.72
 Prednisone8.59 (2.97–21.46)4.94 (2.29–12.87)8.15 (1.81–19.59)0.29
 Dexamethasone6.34 (2.63–12.78)5.04 (2.48–6.98)3.72 (2.42–5.45)0.32
 Hydrocortisone9.53 (4.88–14.28)9.59 (4.25–12.94)8.16 (3.45–12.06)0.92
Timing of corticosteroid initiation
 <7 days330 (57.6)244 (58.0)86 (56.1)0.52
 ≥8 to ≤14 days129 (22.6)92 (21.9)37 (24.2)
 >14 days115 (20.1)85 (18.0)30 (19.6)
Median time from hospital admission to corticosteroid administration (days)5.96 (3.08–10.62)5.86 (2.97–10.51)6.25 (3.58–11.29)0.58
Adjuvant therapies among corticosteroid users
 Hydroxychloroquine420 (73.2)321 (76.2)99 (64.7)0.74
 Azithromycin397 (69.2)289 (68.7)108 (70.6)0.55
 Tocilizumab20 (3.5)13 (3.1)7 (4.6)0.62
 Anticoagulation255 (44.4)191 (45.3)65 (42.4)0.55
  • *Median time of drug administration—(25% percentile–75% percentile).

  • †Anticoagulation—heparin, enoxaparin, apixaban, rivaroxaban.